Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns AJWM, Dursun S, Paats MS, Tjan-Heijnen VCG, van der Leest C, Dingemans AC, Mathijssen RHJ, van de Garde EMW, Souverein P, Driessen JHM, Hendriks LEL, van Geel RMJM, Croes S.
van Veelen A, et al. Among authors: van de garde emw.
Int J Cancer. 2024 Jan 15;154(2):332-342. doi: 10.1002/ijc.34742. Epub 2023 Oct 15.
Int J Cancer. 2024.
PMID: 37840304